Despite advances in surgery and adjuvant therapy, brain tumors represent one of the leading causes of cancer-related mortality and morbidity in both adults and children.
youngest sibling in the systems biology family, can not only complement genomics, transcriptomics and proteomics, but also add a novel dynamic prospective to precision medicine and drug discovery. 6, 7 There are numerous challenges to treating GBM tumors. The blood brain barrier and poor tumor vasculature restrict many potential drugs from reaching these tumor cells. Furthermore, these tumors are characterized by highly disordered vascular proliferation and pseudopalisading necrosis, in which necrotic hypoxic foci are surrounded by dense migrating tumor cells escaping hypoxia. A pattern of disordered vascular growth, necrosis, hypoxia, and cell migration contributes to the infiltrative nature and poor prognosis of these tumors. 8 Given the prevalence of hypoxia and migratory nature of tumor cells, angiogenesis is necessary for these cells to receive adequate access to oxygen and nutrients. It is not surprising that GBM has been classified as one of the most endothelial-dependent tumor types. 9 For this reason, the VEGF inhibitor bevacizumab has been implemented as an antiangiogenic agent in the treatment of refractory tumors. Unfortunately, although bevacizumab extends progression-free survival, it fails to extend overall survival in GBM patients, indicating that initially sensitive tumors develop resistance to anti-angiogenic therapy over time. 10 Tumor hypoxia has been quantified in patients treated with bevacizumab, and high tumor hypoxia (measured by hypoxia marker CA9) has been linked to increased resistance to treatment and poor patient prognosis, even though many highly hypoxic tumors initially show radiographic response to bevacizumab. 11 Hypoxic resistance is not unique to anti-angiogenic therapy, and is a feature of radiation therapy and a variety of chemotherapies in numerous cancer types. 12 It is likely that long-term metabolic reprogramming is involved in the development of this treatment resistance.
Recurrent tumor growth under hypoxic conditions would require proliferating cells to be less reliant on the citric acid cycle and oxidative phosphorylation for energy production and more reliant on glycolysis and lactic acid production. Malignant cells are typically more reliant on glycolysis than oxidative phosphorylation for their energy needs even in normoxia, a phenomenon known as the Warburg effect, but this metabolic behavior is further exacerbated under hypoxia. 12 This metabolic feature can be beneficial for cells subjected to radiation, by decreasing their oxidative stress load. Another possible explanation for hypoxic resistance to therapy is that metabolic adaptations under hypoxia channel metabolites into alternative pathways that may confer long-term advantages onto chronically hypoxic tumors. These alternatively elevated pathways can lead to the synthesis of structural or signalling metabolites including lipids, amino acids, and nucleic acids, and other metabolites necessary for cellular proliferation, tumor growth, and tumor cell survival. Metabolic adaptations in GBM may also be playing an important role in evasion of the immune system by tumor cells, as well as maintenance of tumor stem cells, which are highly resistant to stresses induced by chemotherapy and radiation. [13] [14] [15] Metabolomic analysis will help determine the important pathways that can be targeted in order to combat treatment resistance in glioma. Beyond adult gliomas, metabolic patterns are useful in differentiating and determining the prognosis of different paediatric brain tumor types. [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] Further work needs to be done to translate metabolic findings into potential treatment targets Fig. 1 .
Metabolomics refers to the untargeted and targeted analyses of the metabolome, that is, the complete set of all the endogenous and the exogenous metabolites (small molecules <3000 Da) present in a biological system such as cells, tissues, and biofluids (eg, cerebrospinal fluid [CSF] , plasma, urine, and saliva). 28 
| METABOLIC PROFILE ANALYSIS METHODS
Methods to analyze small metabolites in biological samples can be essentially divided into three methodological approaches: untargeted metabolomics, metabolic profiling, also referred to as targeted metabolomics, and stable isotope-resolved metabolomics (SIRM). [48] [49] [50] [51] Metabolic profiling is commonly used to identify and quantify a predefined list of metabolites from a biological sample. 52 On the other hand, untargeted metabolomics refers to an unbiased, hypothesis-free analysis of all detectable metabolites from a biological sample. 31, 48 Despite the huge amount of features detected using an untargeted metabolomics analysis, often this approach represents a compromise between specificity and selectivity, and time of acquisition. In fact, a comprehensive analysis cannot be achieved by using one single analytical technology or by performing the metabolic analysis in a single acquisition. However, an untargeted approach is advantageous in pinpointing metabolites that are highly affected by the system perturbation (for instance, disease or pharmacological intervention). Once the metabolic pathway of interest is identified using an untargeted approach, a targeted metabolic profiling may sometimes be required to increase the number of metabolites associated with that specific pathway. 31, 49 In spite of all the technological advances of the analytical methods, the identification and quantification of several metabolites can be trivial and requires continuing development of appropriate protocols. A more in depth discussion of some of these metabolites will be reviewed later in the "Detection of critical metabolites" section.
In addition to untargeted and targeted metabolomics, SIRM is a robust metabolic approach for dynamically tracing the fate of selected isotopically labelled compounds and unequivocally assign the metabolic alteration to a specific pathway. This approach requires a priori selection of the tracers that need to be replaced in culture media (eg, glucose, glutamine) or injected in a living organism before sample collection. 53 For SIRM applications, NMR spectroscopy has been historically used for structural elucidation of metabolic tracers by determining the site-specific incorporation by in vivo and in vitro 13 C NMR. [69] [70] [71] [72] Alternatively, two dimensional NMR spectroscopy 73, 74 acquired using a large number of increments on the indirect dimension can provide 13 C-13 C scalar coupling information and thus valuable information to determine the exact position of the labelled atom. 75,76 13 C NMR has been successfully applied to study tumor metabolism of primary human GBM and IDH-mutated gliomas by infusion of 13 C-labeled nutrients (glucose, acetate and glutamine).
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FIGURE 2 Workflow for brain tumor metabolomics. Metabolites are extracted from biological samples (cell, tissue, and biofluids) with the addition of internal standards using liquid-liquid extraction; polar and non-polar aliquots are dried and subsequently analyzed by liquid chromatography-mass spectrometry (LC-MS) and nuclear magnetic resonance spectroscopy (NMR). The raw data is processed afterwards using metabolomics software such as XCMS and SEIVE etc. to perform peak alignment and identification. The processed data further normalized for multivariate statistical analysis. Ultimately, the workflow provides global metabolite profile and signature metabolites of different samples groups (diseased vs healthy and treatment vs control etc.)
Magnetic resonance spectroscopic imaging (MRSI) is a non- 
| One-carbon metabolism
Formate plays a central role in multiple biochemical pathways including one carbon metabolism and de novo purine biosynthesis, and its analysis is challenging due to its small molecular weight (46 g/mol). 167 NMR is routinely used to measure formate. 168 In addition, GC coupled with FID, ECD, and MS have been reported and involve esterification of formic acid prior to analysis using a variety of derivatizing reagents. [169] [170] [171] [172] [173] [174] [175] Selection of a suitable derivatizing reagent, optimum concentration of reagents, and catalysts, and pH of buffer solution are the key concerns in analytical development due to instability and easily Based on the relevance of these key intermediate targets of several chemotherapeutic treatments, optimized and more highthroughput protocols will be developed in the near future.
| METABOLOMICS STUDIES IN ADULT BRAIN TUMORS
Altered cell metabolism is one of the hallmarks of cancer and plays a key role in promoting tumorigenesis, sustaining tumor growth, and improving tumor resistance to chemotherapy. [178] [179] [180] Metabolic alteration of glucose, fatty acid, and anaplerotic amino acid metabolism has been associated with malignant transformation and drug resistance in brain cancer. 181 Recently, metabolomics studies indicated that (Table 1) . 67, [187] [188] [189] [190] [191] [192] [193] [194] [195] [196] [197] For instance, D-2-HG is a well-established metabolic biomarker for tumor grade classification PANDEY ET AL. 191, 192 CSF samples of malignant glioma patients (GBM vs anaplastic astrocytomas and anaplastic oligoastrocytomas)
Ex vivo LC-MS and GC-MS Citric acid↑, isocitric acid↑, lactic acid↑, 2-aminopimelic acid↑, indole↓, indoleacrylic acid↓, and anthranilic acid↓ 193, 194 Tissue samples from GBM vs oligodendrogliomas and chemotherapeutic response in low-grade gliomas (LGGs). 155, 156, 198, 199 Mutations in the metabolic enzyme isocitrate dehydrogenase 1 (IDH1) have been identified in LGGs and in secondary GBM, and result in a NADPH-dependent reduction of α-ketoglutarate to D-2-HG. 155, 156, 198 IDH mutations associated with an elevated level of D-2-HG contribute to tumor formation and malignant progression in gliomas, however, a high level of D-2-HG is also a predictor of longer survival and good response to temozolomide (TMZ) in LGGs. 155, 156, 200 Another relevant metabolic biomarker associated with glioma grade is myo-inositol (MI), an important osmolyte and substrate for the synthesis of the phosphatidylinositol lipid family. 201, 202 The increased concentration of MI has been reported in many brain disorders that involve astrocyte proliferation. Kallenberg and colleagues reported that MI level was significantly higher in patients with GBM compared to patients with LGGs and control subjects. 202 Several in vivo studies carried out in patients with different grades of astrocytomas have also demonstrated that astrocytomas show low NAA peak and prominent signals from Cho group-containing compounds, and Lac. [203] [204] [205] [206] Malignant tumor cells convert most of glucose into lactic acid by active glycolysis, which increases the cytosolic NADH/NAD + ratio and thereby accelerates lactate dehydrogenase LDH A activity. 194 In GBM, up-regulation of M2 isoform of pyruvate kinase (PK) PKM2 favors aerobic glycolysis, thereby increasing Lac production. 207 A switch to aerobic glycolysis may benefit these tumors during the development of tumor hypoxia by lowering the levels of oxygen consumption needed to sustain energy production. The higher levels of triose phosphate glycolytic intermediates, including phosphoenolpyruvate (PEP) and 3-phosphoglycerate (3-PG), and Lac represent unique markers for gliomas. 194, 198 Recently, Mörén and colleagues performed metabolic profiling on tumor tissue and serum samples from glioma patients and were able to identify a metabolic signature of GBM compared to oligodendrogliomas (Table 1) . 208 Turnover of several metabolites have been reported in this study including cysteine (Cys) which has been found upregulated in serum samples of GBM compared to oligodendrogliomas patients. 208 Cysteine metabolism in brain tumor is gaining considerable interest due to its role in GSH synthesis via the cysteine/glutamate antiporter system x c −. | 2363
In addition to cysteine, other amino acids are of particular interest for brain cancer. For instance, Glu is the main excitatory neurotransmitter in mammalian CNS that regulates brain development and functions. [17] [18] [19] The glutamatergic system plays a crucial role in cell survival, proliferation, and migration of gliomas. 19 Gln metabolizes to α-ketoglutarate and provides energy through substrate level phosphorylation in the tricarboxylic acid (TCA) cycle, thereby acting as metabolic fuel. 20 In GBM, most of the acetyl-CoA for fatty acid or lipid synthesis comes both from glycolysis and glutaminolysis. 21 A recent study has demonstrated that GBM cells convert 90% of glucose and 60% of Gln into Lac or Ala. 21 . The rapid conversion of Gln into Lac (glutaminolysis)
produces sufficient NADPH to support fatty acid synthesis. Previous lipidomic investigations have also been observed lower abundance of total lipids in malignant gliomas or grade IV astrocytoma than the low-grade astrocytomas. 24, 25 These studies suggest that in addition to glucose from anaerobic glycolysis, GBM depends on fatty acids as a fuel source. 23 MRS studies have also been conducted to distinguish between two distinct GBM phenotypes named highly infiltrative nonangiogenic phenotype that shows numerous stem cell markers (low-generation, LG, tumor) and less invasive highly angiogenic phenotype (high-generation, HG, tumor). 26 Findings of this study indicated higher concentrations of Tau, Cho, and Lac in LG tumor and increased concentrations of Cho and MI with decreased concentrations of Glu and NAA in HG tumor. 26 The MRS analysis of temozolomide (TMZ) treated GBM, which involve three tissue types (normal brain parenchyma, tumors treated with three TMZ cycles, and untreated control tumors) was carried out to study metabolic alterations induced by treatment. 27 This study indicated lower saturated fatty acid mobile lipids (MLs) and MI/Gly ratio, and higher total ML, ML polyunsaturated fatty acid signals in treated tumor compared to untreated, and higher MLs, Cho/Cr ratio, Lac, and low NAA signals in untreated tumor compared to normal brain ↑, upregulation; ↓, downregulation; αAAD, α-aminoadipate; Ala, alanine; Asp, aspartate; Cho, choline; Cr, creatine; CSF, cerebrospinal fluid; Cys, cysteine; DIPG, diffuse intrinsic pontine gliomas; GABA, γ-aminobutyrate; GBM, glioblastoma multiforme; Glu, glutamate; Gln, glutamine; GSH, glutathione; GPC, glycerophosphocholine; GPE, glycerophosphoethanolamine; Gly, glycine; HGGs, high-grade gliomas; HGOs, high-grade oligodendrogliomas; 2-HG, 2-hydroxyglutarate; His, histidine; H-tau, hypotaurine; Ile, isoleucine; Lac, lactate; Leu, leucine; LGGs, low-grade gliomas; LGOs, low-grade oligodendrogliomas; Lys, lysine; MI, myo-inositol; MLs, mobile lipids; NAA, N-acetyl-aspartate; PC, phosphocholine; PE, phosphoethanolamine; Phe, phenylalanine; PNET, primitive neuroectodermal tumors; Pro, proline; SI, scyllo-inositol; Tau, taurine; tCr, total creatine; Thr, threonine; TMZ, temozolomide; Tyr, tyrosine; Val, valine. parenchyma. 27 These metabolomics studies have proven their pivotal role in predicting glioma malignancy and prognosis. Results of this study showed that medulloblastoma was characterized by high levels of Cho, GPC, PC, Tau, a slightly increased level of MI, low level of fatty acids, and decreased level of NAA and Cr. 221 Pilocytic astrocytomas showed higher concentrations of fatty acids, amino acids (Ile, Leu and Val), NAA, GABA, and Glu, and lower levels of Cr, MI, and Tau. 221 Paediatric ependymoma was mainly characterized by intense signals of MI and slightly lower levels of GABA, PC, and GPC compared to medulloblastoma. 221 An in vivo MRS study was conducted to predict treatment response of brain tumor (neuroepithelial) in children. Findings of this study demonstrated that patients who responded to chemotherapy or radiation showed higher tCr and lower Cho, Lac, and lipid levels than the patients who did not respond to treatment or were not treated. 222 Also, NAA levels were low regardless of tumor state or treatment response. 222 This study suggested that tCr is the independent predictor of active tumor growth. In a similar context, MRSI analysis performed on children with neuroglial and recurrent primary brain tumors identified the change in Cho/NAA ratio as the most important prognostic indicator of tumor progression in children. [223] [224] [225] Patients with progressive paediatric brain tumors showed significantly higher percent change in Cho/NAA compared to patients with clinically stable paediatric brain tumors. 223 Moreover, an MRSI study identified elevated levels of Cho, lipids, and Lac in high-grade paediatric brain tumors and proposed the metabolic signature as a predictor of clinical grades. 226 Proton- 
